Theratechnologies Inc (TSX:TH)

C$ 1.78 0.09 (5.33%) Market Cap: 81.84 Mil Enterprise Value: 108.22 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Q3 2024 Theratechnologies Inc Earnings Call Transcript
Oct 10, 2024

C$1.75 (+4.79%)

Earnings
Q2 2024 Theratechnologies Inc Earnings Call Transcript
Jul 10, 2024

C$2.01 (-4.29%)

Earnings
Q1 2024 Theratechnologies Inc Earnings Call Transcript
Apr 10, 2024

C$2.01 (-3.83%)

Earnings
Q4 2023 Theratechnologies Inc Earnings Call Transcript
Feb 21, 2024

C$2.29 (+0.88%)

Earnings
Q3 2023 Theratechnologies Inc Earnings Call Transcript
Sep 26, 2023

C$2.29 (-18.51%)

Earnings
Q2 2023 Theratechnologies Inc Earnings Call Transcript
Jul 12, 2023

C$4.64 (-7.94%)

Earnings
Theratechnologies Inc Investors & Analysts: Phase 1 Trial Update Transcript
Jun 13, 2023
Theratechnologies Inc Annual Shareholders Meeting Transcript
May 09, 2023
Q1 2023 Theratechnologies Inc Earnings Call Transcript
Apr 12, 2023

C$4.2 (-2.78%)

Earnings
Q4 2022 Theratechnologies Inc Earnings Call Transcript
Feb 28, 2023

C$5.16 (-1.53%)

Earnings
Q3 2022 Theratechnologies Inc Earnings Call Transcript
Oct 13, 2022

C$11.4 (-1.04%)

Earnings
Q2 2022 Theratechnologies Inc Earnings Call Transcript
Jul 14, 2022

C$11.52 (+9.51%)

Earnings
Q1 2022 Theratechnologies Inc Earnings Call Transcript
Apr 13, 2022

C$12.88 (+0.63%)

Earnings
Q4 2021 Theratechnologies Inc Earnings Call Transcript
Feb 24, 2022

C$14.04 (-8.12%)

Earnings
Theratechnologies Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
Q3 2021 Theratechnologies Inc Earnings Call Transcript
Oct 13, 2021

C$17.72 (+2.07%)

Earnings
Theratechnologies Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Theratechnologies Inc Discuss on Treatment of NASH Key Opinion Leader Webinar Transcript
Sep 13, 2021
Q2 2021 Theratechnologies Inc Earnings Call Transcript
Jul 15, 2021

C$17.68 (-3.91%)

Earnings
Theratechnologies Inc Key Opinion Leader Webinar Transcript
Jun 21, 2021
Theratechnologies Inc Annual Shareholders Meeting Transcript
May 13, 2021
Theratechnologies Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 21, 2021
Q1 2021 Theratechnologies Inc Earnings Call Transcript
Apr 14, 2021

C$18.24 (-5.79%)

Earnings
Q4 2020 Theratechnologies Inc Earnings Call Transcript
Feb 25, 2021

C$15.72 (+0.26%)

Earnings
Q3 2020 Theratechnologies Inc Earnings Call Transcript
Oct 15, 2020

C$11.88 (+8.00%)

Earnings
Theratechnologies Inc. - Special Call Transcript
Sep 10, 2020
Theratechnologies Inc Annual Shareholders Meeting Transcript
Jul 16, 2020
Q2 2020 Theratechnologies Inc Earnings Call Transcript
Jul 15, 2020

C$11.84 (-1.00%)

Earnings
Q1 2020 Theratechnologies Inc Earnings Call Transcript
Apr 14, 2020

C$11.48 (+13.44%)

Earnings
Q4 2019 Theratechnologies Inc Earnings Call Transcript
Feb 25, 2020

C$12.88 (-3.59%)

Earnings
Theratechnologies Inc Corporate Analyst Meeting Transcript
Oct 23, 2019
Q3 2019 Theratechnologies Inc Earnings Call Transcript
Oct 08, 2019

C$19.28 (-12.68%)

Earnings
Q2 2019 Theratechnologies Inc Earnings Call Transcript
Jul 11, 2019

C$24.76 (-0.96%)

Earnings
Theratechnologies Inc to Present New Development Strategy for Tesamorelin Conference Call Transcript
Jun 17, 2019
Q1 2019 Theratechnologies Inc Earnings Call Transcript
Apr 04, 2019

C$32.88 (-5.95%)

Earnings
Katana Biopharma Inc., Theratechnologies Inc. - M&A Call Transcript
Feb 25, 2019
Q4 2018 Theratechnologies Inc Earnings Call Transcript
Feb 21, 2019

C$33.36 (+10.32%)

Earnings

Theratechnologies Inc Discuss on Treatment of NASH Key Opinion Leader Webinar Transcript

Sep 13, 2021 / 04:00PM GMT

Release Date Price: C$18.68 (+0.21%)

Transcript

Operator

Good afternoon, and welcome to the Theratechnologies KOL webinar on tesamorelin for the treatment of nonalcoholic steatohepatitis. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Theratechnologies' website following the conclusion of today's event. I'd now like to turn the call over to our host, Paul LÃ©vesque, President and Chief Executive Officer of Theratechnologies. Paul, please go ahead.

Paul LÃ;vesque

Theratechnologies Inc. - President, CEO & Director

© -

Good afternoon. I would like to welcome everyone today for joining us. I believe we have a very good program for you highlighting the NASH disease area and Theratechnologies' Phase III development program evaluating tesamorelin for the treatment of NASH. The first part will be a panel discussion with leading NASH KOL, Dr. Rohit Loomba, Dr. Stephen Harrison and Dr. Steve Grinspoon followed by an audience Q&A session.

Joining the panel for the Q&A sessions will be Christian Marsolais, Theratechnologies' Chief

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.